CORT earnings call for the period ending March 31, 2019.
News & Analysis: Corcept Therapeutics
The stock ricocheted around, but ultimately posted a monthly gain.
CORT earnings call for the period ending December 31, 2018.
The company announced preliminary full-year 2018 results that fell below Wall Street's expectations.
An investigative report is shining light on some very serious questions about the company. Shareholders absolutely must read it.
It looks like generic versions of the company's Cushing syndrome treatment will hit a roadblock.
Solid revenue growth and pipeline progress from the biotech fueled the rise.
Find out why two tech stocks and a small-cap biotech look like compelling investment opportunities right now.
The pharma company announced second-quarter 2018 earnings results and lowered full-year 2018 revenue guidance.
Corcept's share price took a big hit following news that its core product may face generic competition sooner than anticipated.